Oracle Corporation (ORC.F)
| Previous close | 107.46 |
| Open | 107.52 |
| Bid | 0.00 x 100000 |
| Ask | 0.00 x 100000 |
| Day's range | 107.26 - 107.52 |
| 52-week range | 87.16 - 120.92 |
| Volume | |
| Avg. volume | 545 |
| Market cap | 296.635B |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | 30.39 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.49 (1.39%) |
| Ex-dividend date | 09 Apr 2024 |
| 1y target est | N/A |
- PR Newswire
Oracle Database 23ai Brings the Power of AI to Enterprise Data and Applications
Oracle Database 23ai, the latest release of Oracle's converged database, is now generally available as a broad range of cloud services. This long-term support release includes Oracle AI Vector Search and more than 300 additional major features focused on simplifying the use of AI with data, accelerating app development, and running mission-critical workloads. The new AI Vector Search capabilities enable customers to securely combine search for documents, images, and other unstructured data with
- PR Newswire
Oracle and TIM Collaborate to Accelerate Cloud Adoption in Italy
Oracle and TIM today announced a collaboration to support the increasing demand for cloud services in Italy from public and private sector organizations. As part of the agreement, TIM's business unit dedicated to businesses and the public sector, TIM Enterprise, will integrate Oracle Cloud Infrastructure (OCI) into its portfolio. In addition, TIM will become the host partner for Oracle's second planned cloud region in Italy, which will be located in Turin and hosted in TIM Group's reliable, next
- PR Newswire
Oracle Advances Global RTSM Capabilities to Help Sponsors
6th Clinical Trial Supply Forum -- Helping sponsors and CROs meet the challenges of complex and global clinical trial studies, Oracle today announced new capabilities in Oracle Clinical One Randomization and Trial Supply Management (RTSM). With new enhancements for use, access, and regionalization, Clinical One RTSM users can address dynamic, country-specific regulations and requirements, and gain speed, reliability, and transparency of trials from commencement to closeout.
